

- Access flow measurement 78
 Acetate-free biofiltration 446
 – hemodialysis 446
 Acetic acid 435
 N-acetylglucosamine 183
 Activated coagulation time 473
 – partial thromboplastin time 473
 Acute hepatitis C virus infection 344
 – renal failure 73, 101, 249, 313
 Adhesion molecule 360
 Adsorbent cartridge 505
 Adsorbents, cytokine adsorptive properties 530
 Adsorption 73
 – experiments 530
 Affinity dialysis 84
 AIDS 84
 Albumin 175
 – loss 261
 Anemia 112, 175, 277, 423
 Antigen presentation 510
 Antihypertensive agents 130
 Anti-proliferative drugs 307
 Apoptosis 9, 188
- Bacteria 409, 435
 Bioartificial organs 60
 Biocompatibility 44, 73, 92, 510
 Biofilm 124, 461
 Bioimpedance 301
 Blood loss 112
 – pressure 320
 – purification 428
 – transfusion 453
 Bone morphogenic protein-7 440
 Brain death, hemodynamic effects 143
 Bystander effect, HIV-derived envelope proteins 84
- Calcimimetics 38
 Calcinosis cutis 224
 Calcium 38
 Cardiac surgery 249
 Cardiopulmonary bypass 249
 Cardiovascular disease 6, 21, 285, 293
 – risk 28, 130, 298
 Care models 13
 Carpal tunnel syndrome 124
 Catheter-related infection 416
 Catheter survival 473
 Ceftazidime 435
 Chemokines 73
- Chronic kidney disease 13, 21, 136, 481
 – – –, prevention 6
 – renal failure 73
 – – injury reversal 440
 Clearance, middle molecules 329
 Continuous ambulatory peritoneal dialysis 216
 – hemodiafiltration 188, 416
 – renal replacement therapy 150, 164, 249
 Convective therapy 481
 Cool dialysis 203
 Coronary heart disease 28
 Counter anti-inflammatory response syndrome 164
 C-reactive protein 329, 518
 Creatine kinase 338
 – – MB 338
 Creatinine 435
 Critical care 416
 Cytokines 9, 60, 73, 101, 124, 188, 329, 360, 428, 530
- Daily dialysis 320
 – hemofiltration, end-stage renal disease 481
 Defibrillation threshold 136
 Diabetes 6
 Diabetic nephropathy 130
 Dialysate temperature 203
 Dialysis 301, 409
 – adequacy 367
 – catheter 416
 – efficacy 505
 – fluid, quality 124
 – Outcomes and Practice Patterns Study 175
 – time 55
 Dialyzer reuse 329
 Diffusive dialysis 469
 Dipyridamole 307
 Direct hemoperfusion 530
 Disinfectants 461
 Donors, brain-dead 143
 Driving force, volume transport 92
 Dyslipidemia 28
- Echocardiography 351, 469
 Economics, chronic kidney disease 13
 Endothelin 499
 Endotoxin 124, 329, 409
 End-stage renal disease 60, 73, 351, 481
- Envelope proteins 84
 Epichlorohydrin activation 198
 Erythropoietin 112, 277, 453
 – resistance 423
 European Best Practices Guidelines for Hemodialysis 175
 Extracellular matrix 256
- Feasibility study, acetate-free hemodialysis 446
 Fluid overload 150, 285
 – status 285
- Glucose 183
 – degradation products 44
 gp120 84
 Graft survival 143
 Granulocyte/monocyte adsorption 499
 Growth factors 360
- Health-related quality of life 320
 – – – –, assessment 481
 – – – –, Taiwan 490
 Heart failure 277
 Hemoadsorption 73
 Hemodiafiltration 249
 – techniques 505
 Hemodialysis 9, 78, 112, 175, 210, 293, 298, 307, 320, 329, 338, 351, 367, 423, 453, 461, 490, 510, 518, 525
 Hemodynamic instability 143
 Hemofiltration 249, 428
 Hemoperfusion 73
 Heparin lock 473
 – removal 198
 Hepatocyte growth factor 440
 HIV-derived envelope proteins 84
 Human mercaptalbumin 525
 Hyaluronan 360
 Hypercalcemia 224
 Hypercholesterolemia 28
 Hyperphosphatemia 175
 Hypertension 28, 55, 130, 481
 Hypervolemia 150
 Hypoalbuminemia 210
 Hypotension 338
- Immunoabsorption, cytokines 530
 Immunodysregulation 164
 Immunomodulation 428
 Implantable cardioverter defibrillator 136
 Infection 101

- Inferior vena cava diameter 351
 Inflammation 60, 101, 124, 285, 298
 –, hemodialysis patients 518
 –, systemic markers 329
 Insulin 183
 Interferon- α 344
 Interleukins 101, 188, 360, 428, 518
 Intra-aortic balloon pump 249
 Intradermal tophi 224
 Iron 112, 277
 – deficiency 423
 – loss 122
- Kidney Disease Outcomes Quality Initiative 175
 Kt/V 320, 481
- Left ventricular diastolic function 469
 – – hypertrophy 44, 351
 Lipopolysaccharide 428
 Low-calcium dialysis 224
- Malnutrition-inflammation atherosclerosis 124
 Mathematical model, affinity hemodialysis 84
 – –, renal replacement therapy 367
 Metalloproteinase-9 256
 Microalbuminuria 499
 β_2 -Microglobulin 329, 435, 481
 Microinflammation 28
 Monocyte 510
 Multiple organ failure 188
 Myocardial dysfunction 150
- Nitric oxide 216
 – – synthetic capacity 203
 Nutrition assessment 481
- On-line hemofiltration 261
 – regenerated ultrafiltrate reinfusion 505
 Organ recovery, brain-dead donors 143
 Overhydration 301
 Oxidant stress 518
 Oxidative stress 298, 525
 Oxidized low-density lipoprotein 518
- Paclitaxel 307
 Parathyroid hormone 38
 Peak concentration hypothesis 164
 Peritoneal dialysis 9, 44, 183, 367
 – mesothelial cell 216
 Peritonitis 360
 Phagocytosis 9
 Phosphorus 38
 Plasma adsorption 530
 Plasma filtration 313
 Plasmapheresis 92
 Polyamide membrane 261
 Polyarylethersulfone 329
 Polymethylmethacrylate membrane hemofilter 188
 Polymorphonuclear leukocyte 188
 Polymyxin-B-immobilized fiber 256
 Polyvinylpyrrolidone 329
 Practice patterns, hemodialysis 175
 Pregnancy-associated plasma protein A 298
 Preload dependence, Doppler measurements 469
 Protamine immobilization 198
 Protein intake 210
 Pulse wave velocity 293
 Pyrogens 124
- Reference values, multifrequency bio-impedance analysis 301
 Regenerated ultrafiltrate 505
 Regional citrate anticoagulation 313
 Renal disease 13
 – –, progression 6, 285
 – failure 224, 277, 518
 – osteodystrophy 38
 – replacement therapy 367, 440
 – tubule assist device 60
 Renalin 329
 Renin-angiotensin system 440
 – – blockade 6
 Residual renal function 285
- Saline flush, catheter patency 473
 Secondary hyperparathyroidism 293
 Sensitivity, salt 55
- Sepsis 73, 101, 164, 428, 530
 Sepsis-related organ failure assessment 188
 Septic shock 313
 Serum ionized calcium 469
 SF-36 questionnaire, Chinese version 490
 Slow continuous ultrafiltration 150
 Soluble intercellular adhesion molecule-1 360
 – interleukin-6 receptor 518
 Sorbents 73, 313, 428
 Statins 518
 Stenosis 307
 Systemic inflammatory response syndrome 73, 164, 530
- Thalassemia 453
 Thimerosal 435
 Tissue inhibitor, metalloproteinase-1 256
 Transforming growth factor- β_1 440
 Troponin I 338
 Tuberculosis 224
 Tubular necrosis, acute 60
 Tumor necrosis factor- α 101, 188, 210
- Ulcerative colitis 499
 Ultrafilters 124
 Ultrafiltration failure 44
 Urea kinetic modeling measurements 481
 – nitrogen 435
 – removal 367
 Uremia 9, 28, 505
 Uremic plasma, stimulatory effect 203
 Urokinase 473
- Vascular access 307
 – smooth muscle cells 307
 Vector Doppler 78
 Ventricular arrhythmias 136
 Vitamin D 210
 – – analogs 38
 – – E 510
 Volume control 44
 – overload 55